This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Viral Infections  • Immunization  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The United States has experienced a shortage of inactivated influenza vaccine during the last 3 influenza seasons, leaving many patients at risk.¹ The possibility of extending existing vaccine supplies by using an alternative intradermal route of vaccination that requires smaller doses as a means of "stretching" available doses of influenza vaccine could have important public health implications. This would enable, despite the current limited supply of the vaccine, vaccination of many more patients than would otherwise be possible. During the influenza season of 2004-2005 and facing a shortage of influenza vaccine in our clinics, we consulted with our central institutional review board and decided to study this potential alternative. The AIDS Healthcare Foundation operates 4 major and 5 satellite clinics throughout the Los Angeles (Calif) metropolitan area. Our objective was to compare the immunogenicity and safety of the candidate vaccine administered intradermally at a reduced dose (0.1 mL) with the . . . [Full Text of this Article]

AUTHOR INFORMATION
Homayoon Khanlou, MD; Susan Sanchez, MD; Michele Babaie, MD; Catherine Chien, MD; Gerald Hamwi, MD; Juan-Carlos Ricaurte, MD; Tomiko Stein, MD; Laveeza Bhatti, MD; Paul Denouden, MD; Charles Farthing, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?